We noted one case of discoid SLE converting into a systemic phenotype, with pleuro-pericarditis shortly after the TLR-9 agonist containing DNA vaccine, one case of SLE that had low activity, but where rituximab was deferred, to enhance vaccine efficacy and where patient flared following the DNA vaccine and a third case of dermatomyositis rash flare following an RNA vaccine. Here, TLR9 is linked to dermatomyositis.